All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2006-001084-27 | Phase I/II study of prevention of Colorectal Cancer CRC with Allopurinol in High-Risk Subjects | not-yet-due | |
Ongoing | 2007-007740-10 | Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN) | not-yet-due | |
Ongoing | 2008-005206-39 | Pilot Study: Iron-chelating treatment in patients with Neurodegeneration with Brain Iron Accumulation (NBIA). | not-yet-due | |
Ongoing | 2009-010088-17 | Whole liver iron overload measured by the biosusceptometer Magnetic Iron Detector (MID) in thalassemia and MDS patients treated with deferasirox | not-yet-due | |
Ongoing | 2010-018456-27 | Efficacia diagnostica della metodica 18F-DOPA-PET/TC nello studio del Neuroblastoma: confronto con scintigrafia 123I-MIBG. | not-yet-due | |
Ongoing | 2012-005398-30 | Diagnostic efficacy and prognostic method [18F] DOPA-PET/CT in | not-yet-due | |
Ongoing | 2013-000287-29 | EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: | not-yet-due | |
Completed, but no date | 2014-005140-18 | Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI | bad-data | |
Ongoing | 2015-004824-77 | A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal can... | not-yet-due | |
Ongoing | 2018-000693-30 | EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. | not-yet-due |